Enrollment
The dementia cohort of the Swedish BioFINDER study is consecutively including 450 patients that are diagnosed with dementia after a thorough clinical investigation at the Memory Clinic, Skåne University Hospital, Sweden. The cohort prospectively include dementia patients with Alzheimer’s disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD), frontotemporal dementia (FTD) or other dementias as well as 50 patients with familial Alzheimer’s disease.
Inclusion criteria
- Fulfills the criteria of dementia due to either Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, Parkinson’s disease with dementia or frontotemporal dementia.
Exclusion criteria
- Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.
- Current significant alcohol or substance misuse.
Examinations
- Clinical assessment
- CT and/or advanced MRI
- CSF and blood sampling
- Cognitive tests
- Cell models
- Neurological and motor assessments
Follow-up
Participants are followed with repeated clinical and cognitive assessments every 12 months for at least 3 years to determine disease progression rate and clinical phenotype.